Pharmacological treatment of chronic systolic heart failure: Are we scraping the bottom of the barrel?

Journal of Cardiovascular Medicine

Volumn 11, Issue 12, 2010, Pages 893-905

  Abate, Elena ^a   Sartor, Riccardo ^a   Ceconi, Claudio ^b   Boffa, Giovanni M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

heart failure; pharmacological treatment; trials

Indexed keywords

AMLODIPINE; ATORVASTATIN; BOSENTAN; CONIVAPTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; IRON; IVABRADINE; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TOLVAPTAN; TUMOR NECROSIS FACTOR ANTIBODY; VASOPRESSIN ANTAGONIST;

CLINICAL TRIAL; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FOLLOW UP; HEMODYNAMICS; HUMAN; IRON THERAPY; KIDNEY FUNCTION; MORTALITY; NONHUMAN; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUPPLEMENTATION; SURVIVAL; SYSTOLIC HEART FAILURE; XEROSTOMIA;

CARDIOVASCULAR AGENTS; CHRONIC DISEASE; EVIDENCE-BASED MEDICINE; HEART FAILURE, SYSTOLIC; HUMANS; TREATMENT OUTCOME;

EID: 78649330513     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328339d884     Document Type: Review

References (143)

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93:1137-1146.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline update for the diagnosis and management ofchronic heartfailure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice for the diagnosis and management of chronic heart failure (Writing Committeeto Updatethe 2001 Guidelinesforthe Evaluationand Management of Heart Failure)-developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-e235.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Societyof Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-2442.
4. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart2000; 83:505-510.
5. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341:577-585.
6. Anker SD, von Haehling S. Inflammatory mediators in chronicheartfailure: an overview. Heart2004; 90:464-470.
7. Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail 2004; 10 (Suppl 1): S1-S4.
8. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51:415-426.
9. Diaz A, Bourassa MG, Guertin MC,Tardif JC. Long-term prognosticvalue of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26:967-974.
10. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation 1994; 89:1580-1586.
11. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27:633-641.
12. Masson S, Latini R, Anand IS, Barlera S, Judd D, Salio M, et al., Val-HeFT investigators. The prognostic value of big endothelin-1 in more than 2.300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2006; 12:375-380.
13. Iwanaga Y, Kihara Y, Inagaki K, Inagaki K, Yoneda T, Kaburagi S, et al. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to heart failure in salt-sensitive hypertensive rats. Circulation 1988; 98:2065-2073.
14. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, Dargie HJ, et al. Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol1999; 33:932-938.
15. Cody RJ. The potential role of endothelin as a vasoconstrictor substance in congestive heartfailure. Eur Heart J 1992; 13:1573-1578.
16. Wong-Dusting HK, La M, Rand MJ. Endothelin-1 enhances vasoconstrictor response to sympathetic nerve stimulation and noradrenaline in the rabbit ear artery. Clin Exp Pharmacol Physiol 1991; 18:131-136.
17. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension inchronicheartfailure.The roleoftheendothelium in pathophysiologyand management. Circulation 2000; 102:1718-1723.
18. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903. (Pubitemid 34984638)
19. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary artery hypertension. J Am Coll Cardiol 2003; 41:1380-1386.
20. Guidelines forthe diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society ofCardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
21. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732-736.
22. Sütsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98:2262-2268.
23. Teerlink JR. Recent heart failure trials on neurohormonal modulation (OVERTURE and ENABLE). Approaching the asymptote of efficacy? J Card Fail 2002; 8:124-127.
24. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end fornonselective endothelin antagonism in heartfailure? Int J Cardiol 2002; 85:195-197.
25. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11:12-20.
26. Gottlieb SS. The impact offinally publishing a negative study: newconclusionsaboutendothelin antagonists. J Card Fail 2005; 11:21-22.
27. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension: a multicenter randomized study. Cardiology2008; 109:273-280.
28. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure: part I. Circulation 2002; 105:2099-2106. (Pubitemid 34465274)
29. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al., EARTH investigators. Long-term effect of darusentan on left ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomized double blind, placebo-controlled trial. Lancet 2004; 364:347-354.
30. Goldsmith SR. Baroreflex control of vasopressin secretion in normal Humans. In: Cowley AW, Liard J-F, Ausiello DA, editors. Vasopressin: cellular and integrative functions. New York, New York, USA: Raven Press; 1988. pp. 389-397.
31. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. JAm Coll Cardiol 2005; 46:1785-1791.
32. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008; 118:410-421.
33. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol1983; 1:1385-1390.
34. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
35. Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol1994; 24:583-591.
36. De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. Am J Cardiol 2005; 96 (12A):24L-33L.
37. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52:1540-1545.
38. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Results from a double-blind randomized trial. Circulation 2003; 107:2690-2696.
39. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291:1963-1971.
40. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, et al. Multicenter, randomized, double-blind, placebo-controlled study of the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. JAm Coll Cardiol 2007; 49:2151-2159.
41. Rossi GP. Arginine vasopressin receptor antagonist for heart failure. Awinterclimbing tothe Everest'stip. J Am Coll Cardiol 2007;49:2160-2162.
42. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trial. JAMA 2007; 297:1332-1343.
43. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297:1319-1331.
44. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417-2423.
45. Russel SD, Adams KF Jr, Shaw JP, Gattis WA, O'Connor CM. Results of a twelve week double-blind, placebo controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure. J Card Fail 2003; 9 (Suppl 5):S60.
46. Costanzo MR, Guglin ME, Saltzberg MT,Jessup ML, Bart BA, Teerlink JR, et al., UNLOAD trial investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. JAm Coll Cardiol 2007; 49:675-683.
47. Karozy A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure. A nephrological perspective. Circulation 2008; 117:975-983.
48. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail1996; 3:243-249.
49. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479-1486.
50. Rauchhaus M, Doehner W, Francis DP. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-3067.
51. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokines receptors in advanced heart failure: an analysis of the cytokine database from vesnarinone trial (VEST). Circulation 2001; 103:2055-2059.
52. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
53. Torre-Amione G, Kapadia S, Benedict C, Oral H, Joung JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a reportfrom the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol1996; 27:1201-1206.
54. Torre-Amione G, Vooletich MT, Farmer JA. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs 2000; 59:745-751.
55. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002; 53:822-830.
56. Aikawa R, Nitta-Komatsubara Y, Kudoh S, Takano H, Nagai T, Yazaki Y, et al. Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha. Cytokine 2002; 18:179-183.
57. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92:2303-2312.
58. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy intransgenic micewith cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81:627-635.
59. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99:3224-3226.
60. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103:1044-1047.
61. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594-1602.
62. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, et al. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994; 180:2173-2179.
63. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, ATTACH investigators. Randomized, double-blind, placebo-controlled, pilottrial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation 2003; 107:3133-3140.
64. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994; 90:12-16.
65. Sugamori T, Ishibashi Y, Shimada T, Takahashi N, Sakane T, Ohata S, et al. Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide. Circ J 2002; 66:627-632.
66. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA 1989; 86:6753-6757.
67. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000; 97:5456-5461.
68. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110:149-154.
69. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. JAm Coll Cardiol 2004; 44:959-966.
70. Androne AS, Katz SD, Lund L, Warren M, Pham A, McCamish MA, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107:226-229.
71. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, et al. Etiology of anemia in patients with advanced heartfailure.JAm Coll Cardiol 2006; 48:2485-2489.
72. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
73. Silverberg DS,Wexler D, Blum M,Wollman Y, Schwartz D,Sheps D, et al. The interaction between heartfailure, renal failure and anemia: the cardio-renal anemia syndrome. Blood Purif 2004; 22:277-284.
74. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. JAm Coll Cardiol 2005; 45:391-399.
75. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. JAm Coll Cardiol 2002; 39:1780-1786.
76. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). JAm Coll Cardiol 2003; 41:1933-1939.
77. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92:625-628.
78. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients, a systematic review and meta-analysis. JAm Coll Cardiol 2008; 52:818-827.
79. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. JAm Coll Cardiol 2000; 35:1737-1744.
80. Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154:645.e9-645.e15.
81. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heartfailureand anaemia. Eur Heart J 2007;28:2208-2216.
82. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al., on behalf of the Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526-535.
83. Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008; 155:751.e1-751.e7.
84. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. JAm Soc Nephrol 1994; 4:1809-1813.
85. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 1992; 7:235-239.
86. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43:1010-1014.
87. Topuzovic N. Worsening of left ventricular diastolic function during long term correction of anemia with erythropoietin in chronic hemodialysis patients; assessment by radionuclideventriculography and exercise. Int J Cardiac Imaging 1999; 15:233-239.
88. Young JB, Diaz R, Maggioni AP, McMurray JJV, O'Connor C, Pfeffer MA, et al. Reduction of events with darbepoetin alfa in heart failure (RED-HF) trial [abstract]. J Card Fail 2006; 6 (Suppl 1):S77.
89. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. JAm Coll Cardiol 2007; 50:1657-1665.
90. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51:103-112.
91. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E,Vilas-Boas F, et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 2007; 13:14-17.
92. Alam MG, Krause MW, Shah SV. Parenteral iron therapy: beyond anaphylaxis. Kidney Int 2004; 66:457-458.
93. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50:471-530.
94. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108:839-843.
95. Sola S, Mir MQS, Lerakis S, Tandon N, Khan B. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47:332-337.
96. Strey C, Young J, Molyneux S, George P, Florkowski C, Scott R, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q reductions in chronic heart failure. Atherosclerosis 2005; 179:201-206.
97. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005; 9:684-690.
98. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104:317-324.
99. Hayashidani S,Tsutsui H, Shiomi T,Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105:868-873.
100. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007; 75:10-20.
101. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005; 91:27-31. (Pubitemid 39664987)
102. Scandinavian Simvastatin Survival Study. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344:1383-1389.
103. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3:249-254. (Pubitemid 127674856)
104. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004; 93:1124-1129.
105. Foody J, Shah R, Galusha D, Masoudi F, Havranek E, Krumholz H. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006; 113:1086-1092.
106. Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high dose HMG-CoA reductase inhibition in nondiabetic patients with nonischemic cardiomyopathy and average low density lipoprotein level. JAm Coll Cardiol 2006; 47:338-341.
107. Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitortherapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patientswith chronic systolic heart failure. J Card Fail 2007; 13:1-7.
108. Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, Poole JE, et al., SCD-HeFT investigators. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the sudden cardiac death in heart failure trial (SCD-HeFT). Am Heart J 2007; 153:573-578.
109. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al., CORONA group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261. (Pubitemid 350190755)
110. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1231-1239.
111. Rinfret S, Behlouli H, Eisenberg MJ, Humphries K, Tu JV, Pilote L. Class effects of statins in elderly patients with congestive heart failure: A population-based analysis. Am Heart J 2008; 155:316-323.
112. Velavan P, Huan Loh P, Clark A, Cleland JG. The cholesterol paradox in heart failure. Congest Heart Fail 2007; 13:336-341.
113. Horwich TB, Hernandez AF, Dai D, Yancy CW, Fonarow GC. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008; 156:1170-1176.
114. Von Healing S, Schefold JC, Springer J, Anker SD. The cholesterol paradox revisited: heartfailure, systemic inflammation, and beyond. Heart Fail Clin 2008; 4:141-151.
115. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930-933.
116. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997; 18 (Suppl):S159-S168.
117. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin Eafter myocardial infarction: resultsof theGISSI-Prevenzionetrial. Lancet 1999; 354: 447-455.
118. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897-1903.
119. London B, Albert C, Anderson ME, Giles WR, Van Wagoner DR, Balk E, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007; 116:320-335.
120. Mozaffarian D, Gottdiener JS, Siscovick DS. Intakeoftunaorotherbroiled or baked fish versus fried fish and cardiac structure, function and hemodynamics. Am J Cardiol 2006; 97:216-222.
121. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320:265-271.
122. Di Stasi D, Bernasconi R, Marchioli R, Marfisi RM, Rossi G, Tognoni G, et al. Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. Eur J Clin Pharmacol 2004; 60:183-190.
123. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223-1230.
124. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in postmyocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007; 28:3012-3019.
125. Fox K, Ford I, Steg P, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372:817-821.
126. f current inhibition by ivabradine. Drugs 2007; 67 (Suppl 2):25-33.
127. f current inhibitor ivabradine: safety considerations. Adv Cardiol 2006; 43:79-96.
128. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109:1674-1679.
129. Mulder P, Thuillez C. Heart rate slowing for myocardial dysfunction/heart failure. Adv Cardiol 2006; 43:97-105.
130. De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 2008; 10:550-555.
131. Fox K, Ford I, Steg P, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372:807-816.
132. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. JAm Coll Cardiol 2008; 52:1529-1539.
133. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, et al. Effectof elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004; 94:957-960.
134. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al., CHARM investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heartfailure. Circulation 2006; 113:671-678.
135. Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007; 99 (2A):4A-23A.
136. Patel AN, Genovese JA. Stem cell therapy for the treatment of heart failure. Curr Opin Cardiol 2007; 22:464-470.
137. Menasché P. Skelet al myoblasts for cardiac repair: act II. JAm Coll Cardiol 2008; 52:1881-1883.
138. Reffelmann T, Konemann S, Kloner RA. Promise of blood-and bone marrow-derived stem cell transplantation for functional cardiac repair. Putting it in perspective with existing therapy. JAm Coll Cardiol 2009; 53:305-308.
139. Bartling B, Milting H, Schumann H, Darmer D, Arusoglu L, Koerner MM, et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation 1999; 100 (Suppl 2):216-223.
140. Kim AS, Miller EJ, Young LD. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol 2009; 196: 37-53.
141. Hhjj RJ, del Monte F, Matsui T, Rosenzweig A. Prospectsforgenetherapy for heart failure. Circ Res 2000; 86:616-621.
142. Isner JM. Myocardial gene therapy. Nature 2002; 415:234-239.
143. Sheridan DJ, Heussch G. Threatsto the future of cardiovascular research. Lancet 2009; 373:875-876.